Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3504066 | 1.00 | MAP2K1 (0.55) | MAP2K1CA1CA2SIRT5CA12 | |
| SCHEMBL14637359 | 0.94 | CA1 (0.56) | MAP2K1CA1CA2SIRT5CA12 | |
| SCHEMBL3204645 | 0.89 | CA1 (0.61) | CA1CA2SIRT5CA12CA9 | |
| SCHEMBL29550379 | 0.89 | CA1 (0.61) | CA1CA2SIRT5CA12CA9 | |
| SCHEMBL12841581 | 0.85 | CA9 (0.50) | MAP2K1CA1CA2CA12CA9 | |
| SCHEMBL29396685 | 0.84 | CA1 (0.58) | CA1CA2SIRT5CA12CA9 | |
| SCHEMBL30453914 | 0.84 | CA1 (0.58) | CA1CA2SIRT5CA12CA9 | |
| Bromide SCHEMBL7547474 | 0.84 | MAP1LC3B (0.46) | MAP2K1CA1CA12CA9ALDH1A1 | |
| SCHEMBL16383357 | 0.81 | CA1 (0.63) | CA1CA2SIRT5CA12CA9 | |
| SCHEMBL13853068 | 0.79 | CA1 (0.48) | CA1CA2SIRT5CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12408605-B2 | Haploid embryogenesis | STICHTING WAGENINGEN RESEARCH (NL) | 2025-09-09 | — | — | US | disclosed |
| EP-3151920-B1 | USE OF INHIBITOR OF APOPTOSIS PROTEIN (IAP) ANTAGONISTS IN HIV THERAPY | SANFORD BURNHAM MED RES INST (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12324817-B2 | Method of inducing dedifferentiation of somatic cells with small molecules to prepare rejuvenated mesenchymal stem cells and uses thereof | Shenzhen Alpha Biopharmaceutical Co. Ltd. (CN) | 2025-06-10 | — | — | US | disclosed |
| CN-119670345-A | Battery temperature prediction method, device, medium and battery system | 联合汽车电子有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-118006541-B | Method for dedifferentiating, transdifferentiating and rejuvenating target cells | 云南济慈再生医学研究院有限公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-118006541-A | Method for dedifferentiating, transdifferentiating and rejuvenating target cells | 云南济慈再生医学研究院有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-117887659-A | Method for promoting differentiation of target cells into nerve cells | 云南济慈再生医学研究院有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-110423719-B | Technology for regulating Jak-Stat pathway to differentiate, dedifferentiate and rejuvenate cells and application thereof | 云南济慈再生医学研究院有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-110423721-B | Preparation method and application of younger repair type fibroblast | 云南济慈再生医学研究院有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20240019441-A1 | SETDB1-MICROTUBULE INTERACTION AND USE THEREOF | Ariel Scientific Innovations Ltd. (IL) | 2024-01-18 | — | — | US | disclosed |
| US-20190192521-A1 | Methods of Treating Arid1A-Mutated Cancers With HDAC6 Inhibitors and EZH2 Inhibitors | WISTAR INST (US) | 2019-06-27 | — | — | US | disclosed |
| US-20180213736-A1 | METHOD FOR PRODUCING HAPLOID, DIHAPLOID AND DOUBLED HAPLOID PLANTS BY ISOLATED MICROSPORE CULTURE | VILMORIN & CIE (FR) | 2018-08-02 | — | — | US | disclosed |
| WO-2018034801-A1 | METHODS OF TREATING ARID1A-MUTATED CANCERS WITH HDAC6 INHIBITORS AND EZH2 INHIBITORS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2018-02-22 | — | — | WO | disclosed |
| US-20170305866-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | THE GENERAL HOSPITAL CORPORATION | 2017-10-26 | — | — | US | disclosed |
| US-9512083-B2 | Histone deacetylase 6 selective inhibitors for the treatment of bone disease | THE GENERAL HOSPITAL CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160212956-A1 | HAPLOID EMBRYOGENESIS | STICHTING WAGENINGEN RESEARCH (NL) | 2016-07-28 | — | — | US | disclosed |
| US-20140378385-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | THE GENERAL HOSPITAL CORPORATION (US) | 2014-12-25 | — | — | US | disclosed |
| EP-2734500-A2 | HISTONE DEACETYLASE 6 SELECTIVE INHIBITORS FOR THE TREATMENT OF BONE DISEASE | The General Hospital Corporation (US) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013013113-A2 | HISTONE DEACETYLASE 6 SELECTIVE INHIBITORS FOR THE TREATMENT OF BONE DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20100247543-A1 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS, S.A. (ES) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378385-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | HDAC1, HDAC6, HDAC9 | MAP2K1 1721/4885CA1 2106/4885CA2 2034/4885 |
| US-20190192521-A1 | Methods of Treating Arid1A-Mutated Cancers With HDAC6 Inhibitors and EZH2 Inhibitors | EZH2, HDAC6, HDAC1 | MAP2K1 2003/4885CA1 1212/4885CA2 2170/4885 |
| US-20170305866-A1 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | HDAC1, HDAC6, HDAC9 | MAP2K1 1721/4885CA1 2106/4885CA2 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.